PIOGLITAZONE THERAPY FOR INFLAMMATORY PATHWAY COMPONENT OF INSULIN RESISTANCE

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。确定噻唑烷二酮(TZD)吡格列酮是否通过引起炎症信号通路成分的有益改变来改善胰岛素敏感性，吡格列酮治疗是否预防或减轻脂肪诱导的胰岛素抵抗，这是否也是由于药物诱导的炎症途径分子成分的有利改变，确定吡格列酮导致血糖、胰岛素和FFA水平降低以及胰岛素敏感性和脂肪组织重塑的时间进程，以确定药物治疗是否发生脂肪细胞重塑，这是否是胰岛素敏化的参与机制，以及吡格列酮是否减缓胰岛素抵抗中胰岛素作用的异常动力学。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Determine whether the thiazolidinedione(TZD) pioglitazone improves insulin sensitivity by causing beneficial alterations in components of the inflammatory signaling pathway, whether pioglitazone treatment prevents, or attenuates, fat-induced insulin resistance, and whether this is also due to drug induced favorable alterations in inflammatory pathway molecular components, determine the time course over which pioglitazone leads to a decrease in glucose, insulin, and FFA levels, as well as insulin sensitivity and adipose tissue remodeling to determine whether adipocyte remodeling occurs with drug treatment and whether this is a participatory mechanism in insulin sensitization, and whether pioglitazone attenuates abnormal kinetics of insulin action present in insulin resistance.